EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2

Xu Li, Yong Suk Cho, Yuhong Han, Mengmeng Zhou, Yuchen Liu, Yingzi Yang, Shu Zhuo, Jin Jiang

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2025.108430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Xu Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: lixu@ahmu.edu.cn. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Protein Serine-Threonine Kinases, Transcription Factors, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevailing view in the cancer field is that Hippo (Hpo) signaling pathway functions as a tumor suppressor pathway by blocking the oncogenic potential of the pathway effectors Yes1-associated transcriptional regulator (YAP)/transcriptional coactivator with PDZ-binding motif. However, YAP can also function as a context-dependent tumor suppressor in several types of cancer including clear cell renal cell carcinomas (ccRCCs). We find that, in addition to inhibiting hypoxia-inducible factor 2α, a major oncogenic driver in Von Hippel-Lindau-/- ccRCC, YAP also blocks nuclear factor κB (NF-κB) signaling in ccRCC to inhibit cancer cell growth under conditions where hypoxia-inducible factor 2α is dispensable. Mechanistically, YAP inhibits the expression of Zinc fingers and homeoboxes 2 (ZHX2), a Von Hippel-Lindau substrate and critical cofactor of NF-κB in ccRCC. Furthermore, YAP competes with ZHX2 for binding to the NF-κB subunit p65. Consequently, elevated nuclear YAP blocks the cooperativity between ZHX2 and the NF-κB subunit p65, leading to diminished NF-κB target gene expression. Pharmacological inhibition of Hpo kinase blocked NF-κB transcriptional program and suppressed ccRCC cell growth, which can be rescued by overexpression of ZHX2 or p65. Our study uncovers a crosstalk between the Hpo and NF-κB/ZHX2 pathways and its involvement in ccRCC growth inhibition, suggesting that targeting the Hpo pathway may provide a therapeutical opportunity for ccRCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellProtein Serine-Threonine KinasesTranscription FactorsSignal TransductionAdaptor Proteins, Signal TransducingKidney NeoplasmsHomeodomain ProteinsPhosphoproteinsTranscription Factor RelANF-kappa BHumansYAP-Signaling ProteinsHippo Signaling PathwayCell Line, TumorCell ProliferationCell Cycle ProteinsAnimalsMiceVon Hippel-Lindau Tumor Suppressor ProteinGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

HippoNF-κBTEADYAPZHX2cancerccRCCp65

Substanzen

Protein Serine-Threonine KinasesTranscription FactorsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingYAP1 protein, humanHomeodomain ProteinsPhosphoproteinsTranscription Factor RelANF-kappa BCell Cycle Proteins

Autor:innen und Institutionen

  • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: lixu@ahmu.edu.cn.
  • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Department of Math and Sciences, Tarrant County College-NE Campus, Hurst, Texas, USA.
  • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Developmental Biology, Harvard School of Dental Medicine, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Boston, Massachusetts, USA; Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.
  • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address:…

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health National Cancer Institute
  • Welch Foundation
  • National Institutes of Health
  • NIH National Institute of General Medical Sciences

Zitieren

APA

Li, X., Cho, Y. S., Han, Y., Zhou, M., Liu, Y., Yang, Y., Zhuo, S., & Jiang, J. (2025). The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108430

Vancouver

Li X, Cho YS, Han Y, Zhou M, Liu Y, Yang Y, et al. The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108430

BibTeX
@article{Li2025,
  author = {Li, Xu and Cho, Yong Suk and Han, Yuhong and Zhou, Mengmeng and Liu, Yuchen and Yang, Yingzi and Zhuo, Shu and Jiang, Jin},
  title = {The Hippo pathway effector YAP inhibits NF-κB signaling and ccRCC growth by opposing ZHX2},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.108430}
}
Kostenlos starten →